5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs

Summary of the technology

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs
Project ID : 47-2020-10890

Details of the Technology Offer

This study will test the hypothesis that treatment with a peptide comprising five units (5-MER), which is administered by injection or oral delivery, will substantially reduce chronic inflammation of the upper respiratory tract and lungs, thus ameliorating the effects of the Coronavirus disease. This will be achieved by targeting a major pro-inflammatory protein called SAA which plays an active role in the development of the disease. Furthermore, it is anticipated that the 5-MER peptide may also activate genes that provide resistance to chronic inflammation mediated by Coronavirus.

Prof. Naor’s research is based on his lab’s finding that a synthetic very short peptide, substantially reduced inflammation in models of rheumatoid arthritis, inflammatory bowel diseases and multiple sclerosis. Studies in his lab point to Serum Amyloid A (SAA) as the target for this peptide, which is also capable of activating genes that may contribute to resistance against chronic inflammations. In SARS, the previous Coronavirus global epidemic disease, SAA was found to increase significantly and was proposed as a suitable marker for the disease. The Naor lab has already shown the 5-MER peptide inhibits inflamed tissues stimulated with SAA.

Project manager

Keren-Or Amar
VP, Business Development, Healthcare

Project researchers

David Naor
HUJI, School of Medicine - IMRIC
Immunology and Cancer Research

Related Keywords

  • Biological Sciences
  • Virus, Virology / Antibiotics / Bacteriology
  • Infectious Diseases
  • Covid-19
  • covid-19
  • coronavirus
  • respiratory
  • inflammation

About Yissum - Research Development Company of the Hebrew University

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Yissum - Research Development Company of the Hebrew University

Never miss an update from Yissum - Research Development Company of the Hebrew University

Create your free account to connect with Yissum - Research Development Company of the Hebrew University and thousands of other innovative organizations and professionals worldwide

Yissum - Research Development Company of the Hebrew University

Send a request for information
to Yissum - Research Development Company of the Hebrew University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support